Maegim한국어

바이오플러스

099430KOSDAQSector: Pharma & Biotech
₩3,605▼ 0.14%Market cap ₩222.2BAs of Jul 21, 2026 close · updated once daily
B
Grade B61.2 ptsTop 31% of 2,523 stocks
Financial strength
61.4
Growth momentum
55.9
Price attractiveness
64.7

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

61.4
How much debt does it carry relative to equity?
Debt-to-equity ratio
46.2%
✓ Above median · Top 45.3% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
83.8%
✗ Below median · Top 81.5% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
16.5%
✓ Above median · Top 10.5% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
8.6%
✓ Above median · Top 17.3% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

55.9
How much did revenue grow in a year?
Revenue growth (YoY)
36.9%
✓ Above median · Top 15.8% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
17.0%
✓ Above median · Top 15.7% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-36.6%
✗ Below median · Top 77.9% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-40.6%
✗ Below median · Top 66.9% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

64.7
Is the price expensive relative to earnings?
P/E (price-to-earnings)
14.8x
✓ Above median · Top 21.7% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
1.27x
✓ Above median · Top 49% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15